TRIM56 Modulates YBX1 Degradation to Ameliorate ZBP1‐Mediated Neuronal PANoptosis in Spinal Cord Injury
Advanced Science · 2024
DOI: 10.1002/advs.202407132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Junsheng Lou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Chin…. Hauptthemen laut MEDLINE: Spinal Cord Injuries, Y-Box-Binding Protein 1, Ubiquitin-Protein Ligases, Tripartite Motif Proteins. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
Spinal cord injury (SCI) is a severe injury to the central nervous system, and its treatment is always a major medical challenge. Proinflammatory cell death is considered an important factor affecting neuroinflammation and the prognosis after injury. PANoptosis, a newly discovered type of proinflammatory cell death, regulates the activation of executioner molecules of apoptosis, pyroptosis and necroptosis through the PANoptosome, providing a new target for therapeutic intervention after SCI. However, its role and regulatory mechanism in SCI are not yet elucidated. Here, based on proteomic data, YBX1 expression is significantly increased in neurons after SCI. Guided by RIP‐seq, subsequent experiments reveal that YBX1 promotes ZBP1 expression by stabilizing the Zbp1 mRNA, thereby aggravating ZBP1‐mediated PANoptosis. Furthermore, the E3 ubiquitin ligase TRIM56 is identified as an endogenous inhibitor of YBX1 via molecular docking and IP/MS analysis. Mechanistically, TRIM56 bound to YBX1 and promoted its ubiquitination, thereby accelerating its degradation. Taken together, these findings reveal a novel function of YBX1 in regulating ZBP1‐mediated PANoptosis in the pathogenesis of SCI and verified that TRIM56 functions as an endogenous inhibitor to promote the ubiquitin‐proteasomal degradation of YBX1, providing new insights into SCI treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, China.
- Obstetrics and Gynecology Hospital, Institute of Reproduction and Development, Fudan University, Shanghai, 200090, China.
- Department of Orthopeadics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, No. 261 Huansha Road, Hangzhou, 310006, China.
- Department of Critical Care Medicine, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
- Department of Orthopeadics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027, China.
ORCID-Profile: Junsong Wu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Lou, J., Mao, Y., Jiang, W., Shen, H., Fan, Y., Yu, Q., Zhou, C., Wei, Z., Zhou, K., Jin, M., & Wu, J. (2024). TRIM56 Modulates YBX1 Degradation to Ameliorate ZBP1‐Mediated Neuronal PANoptosis in Spinal Cord Injury. Advanced Science. https://doi.org/10.1002/advs.202407132
Vancouver
Lou J, Mao Y, Jiang W, Shen H, Fan Y, Yu Q, et al. TRIM56 Modulates YBX1 Degradation to Ameliorate ZBP1‐Mediated Neuronal PANoptosis in Spinal Cord Injury. Advanced Science. 2024. doi:10.1002/advs.202407132
BibTeX
@article{Lou2024,
author = {Lou, Junsheng and Mao, Yiting and Jiang, Wu and Shen, Honghao and Fan, Yunpeng and Yu, Qing and Zhou, Conghui and Wei, Ziyao and Zhou, Kailiang and Jin, Mengran and Wu, Junsong},
title = {TRIM56 Modulates YBX1 Degradation to Ameliorate ZBP1‐Mediated Neuronal PANoptosis in Spinal Cord Injury},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202407132}
}
EUVIMED